78 related articles for article (PubMed ID: 31920132)
21. Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
Sullivan RJ
Lancet; 2020 May; 395(10236):1524-1525. PubMed ID: 32416774
[No Abstract] [Full Text] [Related]
22. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Carlino MS; Menzies AM; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Guminski AD; Kefford R; Wu H; Ibrahim N; Homet Moreno B; Long GV
Clin Cancer Res; 2020 Oct; 26(19):5086-5091. PubMed ID: 32605909
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of nivolumab in advanced melanoma: a drug review.
Specenier P
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):13-28. PubMed ID: 33225752
[No Abstract] [Full Text] [Related]
24. Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.
Hong AM; Waldstein C; Shivalingam B; Carlino MS; Atkinson V; Kefford RF; McArthur GA; Menzies AM; Thompson JF; Long GV
Eur J Cancer; 2021 Jan; 142():10-17. PubMed ID: 33207293
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
Joseph RW; Liu FX; Shillington AC; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Saretsky TL; Pickard AS
Qual Life Res; 2020 Oct; 29(10):2651-2660. PubMed ID: 32405921
[TBL] [Abstract][Full Text] [Related]
26. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
27. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
28. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
[TBL] [Abstract][Full Text] [Related]
29. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
Babacan NA; Eroglu Z
Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
[TBL] [Abstract][Full Text] [Related]
30. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
[TBL] [Abstract][Full Text] [Related]
31. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives.
Zhao Y; Liu L; Weng L
Front Pharmacol; 2021; 12():714483. PubMed ID: 34305619
[TBL] [Abstract][Full Text] [Related]
32. Anorectal mucosal melanoma.
Alvarez J; Smith JJ
Semin Colon Rectal Surg; 2023 Dec; 34(4):. PubMed ID: 38746826
[TBL] [Abstract][Full Text] [Related]
33. A Theranostic Approach to Imaging and Treating Melanoma with
Jiao R; Allen KJH; Malo ME; Yilmaz O; Wilson J; Nelson BJB; Wuest F; Dadachova E
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568672
[TBL] [Abstract][Full Text] [Related]
34. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.
Rubatto M; Sciamarrelli N; Borriello S; Pala V; Mastorino L; Tonella L; Ribero S; Quaglino P
Front Med (Lausanne); 2022; 9():959289. PubMed ID: 36844955
[TBL] [Abstract][Full Text] [Related]
35. Survival Mechanisms of Metastatic Melanoma Cells: The Link between Glucocorticoids and the Nrf2-Dependent Antioxidant Defense System.
Obrador E; Salvador-Palmer R; López-Blanch R; Oriol-Caballo M; Moreno-Murciano P; Estrela JM
Cells; 2023 Jan; 12(3):. PubMed ID: 36766760
[TBL] [Abstract][Full Text] [Related]
36. Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment.
Han J; Agarwal A; Young JN; Owji S; Luu Y; Poplausky D; Yassky D; Estrada Y; Ungar J; Krueger JG; Gulati N
Sci Rep; 2022 Dec; 12(1):22364. PubMed ID: 36572780
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study.
Wang C; Zoungas S; Yan M; Wolfe R; Haydon A; Shackleton M; Voskoboynik M; Moore M; Andrews MC; Nicholls SJ; Mar V
Cardiooncology; 2022 Dec; 8(1):23. PubMed ID: 36461057
[TBL] [Abstract][Full Text] [Related]
38. Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma.
Kuo HY; Han MZ; Liao CH; Lin YJ; Wang CT; Chen SH; Chang TT; Chen PJ; Lin SH; Chen CY; Chuang CH; Wu IC; Wu JS; Hong TC; Hsieh MT; Lee YC; Wu HT; Tsai HM
Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365082
[TBL] [Abstract][Full Text] [Related]
39. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.
Qian MF; Betancourt NJ; Pineda A; Maloney NJ; Nguyen KA; Reddy SA; Hall ET; Swetter SM; Zaba LC
Oncologist; 2023 Mar; 28(3):268-275. PubMed ID: 36302223
[TBL] [Abstract][Full Text] [Related]
40. Targeting Melanin in Melanoma with Radionuclide Therapy.
Allen KJH; Malo ME; Jiao R; Dadachova E
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
